Чланци са овлашћеним јавним приступом - Dwight Koeberl, MD,PhDСазнајте више
Није доступно нигде: 1
Induction of autophagy improves hepatic lipid metabolism in glucose-6-phosphatase deficiency
BL Farah, DJ Landau, RA Sinha, ED Brooks, Y Wu, SYS Fung, T Tanaka, ...
Journal of hepatology 64 (2), 370-379, 2016
Овлашћења: National Medical Research Council, Singapore
Доступно негде: 60
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
PS Kishnani, PC Goldenberg, SL DeArmey, J Heller, D Benjamin, ...
Molecular genetics and metabolism 99 (1), 26-33, 2010
Овлашћења: US National Institutes of Health
Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid α-glucosidase
F Puzzo, P Colella, MG Biferi, D Bali, NK Paulk, P Vidal, F Collaud, ...
Science translational medicine 9 (418), eaam6375, 2017
Овлашћења: US National Institutes of Health, European Commission
IRF2BPL is associated with neurological phenotypes
PC Marcogliese, V Shashi, RC Spillmann, N Stong, JA Rosenfeld, ...
The American Journal of Human Genetics 103 (2), 245-260, 2018
Овлашћења: US National Institutes of Health, Howard Hughes Medical Institute, Research …
The role of hepatocyte hemojuvelin in the regulation of bone morphogenic protein-6 and hepcidin expression in vivo
AS Zhang, J Gao, DD Koeberl, CA Enns
Journal of Biological Chemistry 285 (22), 16416-16423, 2010
Овлашћења: US National Institutes of Health
Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice
J Gao, J Chen, I De Domenico, DM Koeller, CO Harding, RE Fleming, ...
Blood, The Journal of the American Society of Hematology 115 (16), 3374-3381, 2010
Овлашћења: US National Institutes of Health
Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease
B Sun, MD Kulis, SP Young, AC Hobeika, S Li, A Bird, H Zhang, Y Li, ...
Molecular Therapy 18 (2), 353-360, 2010
Овлашћења: US National Institutes of Health
Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease
P Zhang, B Sun, T Osada, R Rodriguiz, XY Yang, X Luo, AR Kemper, ...
Human gene therapy 23 (5), 460-472, 2012
Овлашћења: US National Institutes of Health
Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus–mediated gene therapy
B Sun, SP Young, P Li, C Di, T Brown, MZ Salva, S Li, A Bird, Z Yan, ...
Molecular Therapy 16 (8), 1366-1371, 2008
Овлашћења: US National Institutes of Health
The circular RNA circSKA3 binds integrin β1 to induce invadopodium formation enhancing breast cancer invasion
WW Du, W Yang, X Li, L Fang, N Wu, F Li, Y Chen, Q He, E Liu, Z Yang, ...
Molecular therapy 28 (5), 1287-1298, 2020
Овлашћења: Canadian Institutes of Health Research, National Natural Science Foundation …
Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle
DD Koeberl, X Luo, B Sun, A McVie-Wylie, J Dai, S Li, SG Banugaria, ...
Molecular genetics and metabolism 103 (2), 107-112, 2011
Овлашћења: US National Institutes of Health
Gene therapy for glycogen storage diseases
PS Kishnani, B Sun, DD Koeberl
Human molecular genetics 28 (R1), R31-R41, 2019
Овлашћења: US National Institutes of Health
Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction
S Han, G Ronzitti, B Arnson, C Leborgne, S Li, F Mingozzi, D Koeberl
Molecular Therapy Methods & Clinical Development 4, 126-136, 2017
Овлашћења: US National Institutes of Health
β2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease
DD Koeberl, S Li, J Dai, BL Thurberg, D Bali, PS Kishnani
Molecular genetics and metabolism 105 (2), 221-227, 2012
Овлашћења: US National Institutes of Health
Hepatic mitochondrial dysfunction is a feature of glycogen storage disease type Ia (GSDIa)
BL Farah, RA Sinha, Y Wu, BK Singh, A Lim, M Hirayama, DJ Landau, ...
Scientific reports 7 (1), 44408, 2017
Овлашћења: US National Institutes of Health, National Medical Research Council, Singapore
A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia
J Zhou, LR Waskowicz, A Lim, XH Liao, B Lian, H Masamune, S Refetoff, ...
Thyroid 29 (8), 1158-1167, 2019
Овлашћења: US National Institutes of Health, National Medical Research Council, Singapore
Person ability scores as an alternative to norm-referenced scores as outcome measures in studies of neurodevelopmental disorders
CA Farmer, AJ Kaat, A Thurm, I Anselm, N Akshoomoff, A Bennett, L Berry, ...
American journal on intellectual and developmental disabilities 125 (6), 475-480, 2020
Овлашћења: US National Institutes of Health
Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia
LR Waskowicz, J Zhou, DJ Landau, ED Brooks, A Lim, ZA Yavarow, ...
Human molecular genetics 28 (1), 143-154, 2019
Овлашћења: US National Institutes of Health, National Medical Research Council, Singapore
Adjunctive β2-agonists reverse neuromuscular involvement in murine Pompe disease
S Li, B Sun, MI Nilsson, A Bird, MA Tarnopolsky, BL Thurberg, D Bali, ...
The FASEB Journal 27 (1), 34, 2013
Овлашћења: US National Institutes of Health
The upstream enhancer elements of the G6PC promoter are critical for optimal G6PC expression in murine glycogen storage disease type Ia
YM Lee, CJ Pan, DD Koeberl, BC Mansfield, JY Chou
Molecular genetics and metabolism 110 (3), 275-280, 2013
Овлашћења: US National Institutes of Health
Публикације и информације о финансирању аутоматски одређује рачунарски програм